Evidence map›Paper›PMID 41180483›Full record

ArticlePeerJ2025

Modulation of

Amal Alamoudi, Khlood Alqarni, Arwa Ishaq A Khayyat, Tajamul Hussain, Salman Alamery

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amal AlamoudiBiochemistry Department, College of Sciences, King Saud University, Riyadh, Saudi Arabia.
Khlood AlqarniBiochemistry Department, College of Sciences, King Saud University, Riyadh, Saudi Arabia.
Arwa Ishaq A KhayyatBiochemistry Department, College of Sciences, King Saud University, Riyadh, Saudi Arabia.
Tajamul HussainBiochemistry Department, College of Sciences, King Saud University, Riyadh, Saudi Arabia.
Salman AlameryBiochemistry Department, College of Sciences, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a complex multifactorial disease caused by genetic and epigenetic changes playing a vital role in its development and progression. Chemotherapy remains a major option in the treatment of CRC. However, due to its unintended effects on normal tissue, research on identifying plant-based therapeutic agents as an alternative treatment modality has gained attention. Fisetin, a plant-derived flavonoid, has shown promising effects as an anticancer agent against several human cancers, including colon cancer. However, there is limited research focusing on studying the mechanism of action of fisetin. The

Indexed as

ApoptosisColonic NeoplasmsFlavonoidsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesCaco-2 CellsCell ProliferationCell SurvivalFlavonolsHumansSignal TransductionfisetinFlavonoidsFlavonolsMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesAnticancer agentApoptosisBAX/BCL-2Cell proliferationCellular pathwaysColon cancerFisetinFlavonoidGene expressionPI3K/AKT/mTOR

Identifiers

PMID41180483
PMCPMC12574586

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.